Help Stop Government from Issuing Exclusive License for Medical Cannabis
Category: Medical Marijuana | Posted on Mon, December, 19th 2011 by THCFinder
As you well know, our federal government maintains that marijuana has “no currently accepted medical use” as a schedule I substance per the Controlled Substance Act. Although sixteen states and the District of Columbia have now passed medical marijuana legislation, the Department of Justice (DOJ) continues to enforce federal law and prosecute those who cultivate, distribute, or possess medical marijuana in compliance with state law.
While the DOJ intimidates and incarcerates medical marijuana patients based upon federal position that cannabis has no medical value, another cabinet-level department within the federal executive branch, the Department of Health and Human Services (HHS), holds the legal right to certain medical applications of cannabinoids; since October 2003, the United States of America, as represented by the Department of Health and Human Services, has been official assignee of U.S. Patent #6630507, entitled “Cannabinoids as antioxidants and neuroprotectants. ” The Union of Medical Marijuana Patients (UMMP) has been well aware of this outrageous hypocrisy for several years now.
However, recent developments beg immediate attention and action from the broader community of medical marijuana advocates, as well as from all Americans who disagree with government-driven financial exploitation and monopolization of the very plant for which hundreds of thousands of American citizens are currently incarcerated.
The notion that one federal bureaucracy claims ownership rights to medical marijuana while its sister department prosecutes the patients who depend upon this government patented “invention” is outrageous enough. However, the Union of Medical Marijuana Patients discovered this week that the federal government now intends to grant an exclusive license to “practice the invention embodied in U.S. Patent 6,630,507” to a single New York based pharmaceutical corporation. In accordance with regulations that dictate how exclusive licenses may be granted on Government owned inventions, 37 CFR part 404.7 (a)(1) (i), the HHS published notice of its intentions in the November 17th edition of the Federal Register.
With a posting entitled “Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics to Treat Hepactic Encephalopathy in Humans,” the Department of Health and Human Services announced its plan to grant KannaLife Sciences, Inc. an exclusive license to “development and sale of cannabinoid(s) and cannabidiol(s) based therapeutics as antioxidants and neuroprotectants for use and delivery in humans. ”
- 192,445 Views Category: Odd
- 151,505 Views Category: Fun
- 141,049 Views Category: Culture
- 102,841 Views Category: Culture
- 101,447 Views Category: Culture
- 100,648 Views Category: Fun
- 81,223 Views Category: Culture
- 79,401 Views Category: Odd
- 71,316 Views Category: Fun
- 64,733 Views Category: Fun